Home » Newsletters » BioWorld Science

BioWorld Science

June 16, 2022

View Archived Issues

rs41423247 SNP in NR3C1 gene predicts pneumonia complications in COVID-19

Novel vaccine candidates presented for Lassa fever

Merck & Co. patents orexin OX2 receptor agonists

Denali Therapeutics divulges new LRP3 inflammasome inhibitors

Dunad Therapeutics and collaborators present new GTPase KRAS inhibitors

Merck & Co. identifies new FXIa and/or KLKB1 inhibitors

U.S. researchers divulge new compounds for SARS-CoV-2 infection

Novel GLP-1 receptor agonist with improved oral bioavailability

Variants in the PABP-domain of PABPC1 associated with developmental delay

Genetic variants found in SLC35B2 gene tied to chondrodysplasia with hypomyelinating leukodystrophy

OliX subsidiary mCureX partners with Samyang and GC Pharma to advance mRNA vaccines

Vipergen enters derma drug discovery partnership with LEO Pharma

Lassen presents preclinical data on LASN-01 in preclinical models of skin fibrosis

Aqemia and Sanofi extend collaboration to use AI technology to optimize molecules to treat cancer

Nordic Bioscience and Roche strengthen biomarker collaboration

T cell-targeted vaccine for Coxiella burnetii infection shows promise in animal models

Blood vessel shape predicts what shape the heart is in

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...